论文部分内容阅读
观察抗血管内皮生长因子(VEGF)药物联合激光治疗重度非增殖性糖尿病视网膜病变与传统激光治疗对患者视力及预后的影响.临床病例对照方法研究,对2012年2月至2015年8月在云南省第一人民医院眼科选取经FFA和OCT检查确诊的重度非增殖期糖尿病视网膜病变患者79例158眼.根据自愿原则,选取玻璃体腔穿刺注射雷珠单抗联合全视网光凝者为治疗组,常规PRP者为对照组.分析两组治疗后第1周、第2周、第4周,第2月、第3月、第6月、第9月、第12月视力,黄斑中心视网膜厚度、视网膜血管改变、玻璃体腔等情况.结果表明:两组治疗前有很好的可比性,年龄、视力、黄斑视网膜厚度两组间差异无统计学意义(P<0.05),治疗组在术后第2周、第4周、第2月、第3月、第6月、第12月视力、黄斑视网膜厚度均较对照组有明显改善,12月内视网膜血管改变,玻璃体腔积血、增殖者两组间差异有统计学意义.通过1年的临床观察行玻璃体腔注射抗VEGF药物,同时联合PRP治疗可有效提高患者中心视力,减轻黄斑部水肿,降低玻璃体积血及视网膜新生血管的发生率.
To observe the effect of anti-vascular endothelial growth factor (VEGF) in combination with laser on severe non-proliferative diabetic retinopathy and traditional laser treatment on visual acuity and prognosis of patients.Clinical case control study, from February 2012 to August 2015 in Yunnan First Provincial People’s Hospital of ophthalmology selected FFA and OCT confirmed severe non-proliferative diabetic retinopathy 79 cases 158 eyes .According to the voluntary principle, select the vitreous cavity puncture injection of ranibizumab combined with the whole retinal photocoagulation for the treatment group , Routine PRP as the control group.Analysis of the two groups after treatment 1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months, 9 months, 12 months, visual acuity, macular retinal thickness , Retinal vascular changes, vitreous cavity and so on.The results showed that there was a good comparability between the two groups before treatment, there was no significant difference between the two groups in age, visual acuity and macular retinal thickness (P <0.05) The visual acuity and macular retinal thickness in the second week, the fourth week, the second month, the third month, the sixth month and the twelfth month were significantly improved compared with those in the control group. The retinal vascular changes, vitreous hemorrhage, There are differences between the two groups The significance of the calculation.After one year of clinical observation of intravitreal injection of anti-VEGF drugs, combined with PRP treatment can effectively improve the patient’s central vision, reduce macular edema and reduce the incidence of vitreous hemorrhage and retinal neovascularization.